These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 33178496)

  • 1. Tumor-infiltrating TNFRSF9
    Li Y; Wang Z; Jiang W; Zeng H; Liu Z; Lin Z; Qu Y; Xiong Y; Wang J; Chang Y; Bai Q; Wang Y; Liu L; Zhu Y; Xu L; Xia Y; Guo J; Xu J
    Oncoimmunology; 2020 Oct; 9(1):1838141. PubMed ID: 33178496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral CXCL13
    Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating CD39
    Qi Y; Xia Y; Lin Z; Qu Y; Qi Y; Chen Y; Zhou Q; Zeng H; Wang J; Chang Y; Bai Q; Wang Y; Zhu Y; Xu L; Chen L; Kong Y; Zhang W; Dai B; Liu L; Guo J; Xu J
    Cancer Immunol Immunother; 2020 Aug; 69(8):1565-1576. PubMed ID: 32306075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
    Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NKG2A
    Qiu Y; Liu L; Jiang W; Xu Z; Wang J; Dai S; Guo J; Xu J
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38262706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.
    Ghatalia P; Gordetsky J; Kuo F; Dulaimi E; Cai KQ; Devarajan K; Bae S; Naik G; Chan TA; Uzzo R; Hakimi AA; Sonpavde G; Plimack E
    J Immunother Cancer; 2019 May; 7(1):139. PubMed ID: 31138299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
    Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
    Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
    [No Abstract]   [Full Text] [Related]  

  • 8. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
    Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.
    Jiang W; Zeng H; Liu Z; Jin K; Hu B; Chang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
    Urol Oncol; 2022 Apr; 40(4):166.e15-166.e25. PubMed ID: 34998671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.
    Xu X; Zhang S; Wang Y; Zhu Y; Wang J; Guo J
    Cancer Med; 2023 May; 12(9):10512-10525. PubMed ID: 37031459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
    Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
    Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell combined bioinformatics analysis: construction of immune cluster and risk prognostic model in kidney renal clear cells based on CD8
    Gao H; Sun H; He A; Liu H; Zhang Z; Li D; Mao W; Qian J
    Eur J Med Res; 2024 Jan; 29(1):89. PubMed ID: 38291496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating CD36
    Ao YQ; Gao J; Zhang LX; Deng J; Wang S; Lin M; Wang HK; Ding JY; Jiang JH
    BMC Cancer; 2023 Apr; 23(1):367. PubMed ID: 37085798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune classification of clear cell renal cell carcinoma.
    Su S; Akbarinejad S; Shahriyari L
    Sci Rep; 2021 Feb; 11(1):4338. PubMed ID: 33619294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a Seven-Gene Signature Associated with CD8
    Chen Y; Zhou X; Xie Y; Wu J; Li T; Yu T; Pang Y; Du W
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
    Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of ST3GAL5 as a prognostic biomarker correlating with CD8
    Liu J; Li M; Wu J; Qi Q; Li Y; Wang S; Liang S; Zhang Y; Zhu Z; Huang R; Yan J; Zhu R
    Front Immunol; 2022; 13():979605. PubMed ID: 36172374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.
    Şenbabaoğlu Y; Gejman RS; Winer AG; Liu M; Van Allen EM; de Velasco G; Miao D; Ostrovnaya I; Drill E; Luna A; Weinhold N; Lee W; Manley BJ; Khalil DN; Kaffenberger SD; Chen Y; Danilova L; Voss MH; Coleman JA; Russo P; Reuter VE; Chan TA; Cheng EH; Scheinberg DA; Li MO; Choueiri TK; Hsieh JJ; Sander C; Hakimi AA
    Genome Biol; 2016 Nov; 17(1):231. PubMed ID: 27855702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LINC00887 Fosters Development of Clear Cell Renal Cell Carcinoma via Inhibiting CD8+ T Cell Immune Infiltration.
    Wu J; Lin R; Zhang L; Wei Y; Zhang R; Cai W; Hu W
    Comput Math Methods Med; 2022; 2022():2582474. PubMed ID: 36060659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.